Welcome and introduction (ID 4714)
Targeting the undruggable: what we know about KRAS-mutant NSCLC (ID 4715)
Harnessing the power of biomarkers to treat NSCLC (ID 4716)
Expanding treatment options for KRAS G12C-mutant NSCLC patients (ID 4717)
Future perspectives: Panel discussion (ID 4718)
Summary and close (ID 4719)